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Abstract
Background—Enterovirus D68 (EV-D68) caused a widespread outbreak of respiratory illness in 
the United States in 2014, predominantly affecting children. We describe EV-D68 rates, spectrum 
of illness, and risk factors from prospective, population-based acute respiratory illness (ARI) 
surveillance at a large US pediatric hospital.
Methods—Children <13 years of age with ARI and residence in Hamilton County, Ohio were 
enrolled from the inpatient and emergency department (ED) settings at a children’s hospital in 
Cincinnati, Ohio, from 1 July to 31 October 2014. For each participant, we interviewed parents, 
reviewed medical records, and tested nasal and throat swabs for EV-D68 using real-time reverse-
transcription polymerase chain reaction assay.
Results—EV-D68 infection was detected in 51 of 207 (25%) inpatients and 58 of 505 (11%) ED 
patients. Rates of EV-D68 hospitalization and ED visit were 1.3 (95% confidence interval [CI], 
1.0–1.6) and 8.4 per 1000 children <13 years of age, respectively. Preexisting asthma was 
associated with EV-D68 infection (adjusted odds ratio, 3.2; 95% CI, 2.0–5.1). Compared with 
other ARI, children with EV-D68 were more likely to be admitted from the ED (P ≤ .001), receive 
supplemental oxygen (P = .001), and require intensive care unit admission (P = .04); however, 
mechanical ventilation was uncommon (2/51 inpatients; P = .64), and no deaths occurred.
Conclusions—During the 2014 EV-D68 epidemic, high rates of pediatric hospitalizations and 
ED visits were observed. Children with asthma were at increased risk for medically attended EV-
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D68 illness. Preparedness planning for a high-activity EV-D68 season in the United States should 
take into account increased healthcare utilization, particularly among children with asthma, during 
the late summer and early fall.
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Enterovirus D68 (EV-D68), a member of the Picornaviridae family, was first described in 
1962 in the United States among children with severe lower respiratory tract infection [1]. 
Subsequent reports of EV-D68 had been infrequent and primarily limited to small clusters 
until 2014, when the largest documented nationwide epidemic of EV-D68 respiratory 
disease in the United States occurred [2–4]. From mid-August 2014 through 15 January 
2015, a total of 1153 EV-D68 cases were confirmed in 49 US states and the District of 
Columbia [5]. Children were predominantly affected, and the epidemic resulted in a 
substantial resource burden at certain hospitals and emergency departments [6, 7].
EV-D68 infection primarily manifests as a respiratory illness, including upper and lower 
respiratory tract disease and asthma exacerbation. During the 2014 outbreak, a history of 
asthma or reactive airway disease was common among children with medically attended EV-
D68 infection [8] and in some studies was associated with more severe illness [4, 9].
Coincident with the timing of the US EV-D68 epidemic, Cincinnati Children’s Hospital 
Medical Center (CCHMC) conducted prospective, population-based surveillance for acute 
respiratory illness (ARI) among children <13 years of age in the emergency department 
(ED) and inpatient hospital settings. We describe rates, clinical features, and severity of EV-
D68 infection and evaluate the association between EV-D68 and asthma.
METHODS
Study Population and Design
Children <13 years of age with ARI and residence in Hamilton County, Ohio, which 
includes Cincinnati, were prospectively enrolled from the hospital inpatient and ED settings 
at CCHMC, an academic, tertiary care pediatric hospital with >600 inpatient beds and 35 
pediatric intensive care unit (ICU) beds. Inpatient admissions and ED visits average >33 000 
and >102 000, respectively, annually. Hospitalized children were eligible if they had been 
admitted within the previous 48 hours with ARI, defined by admission diagnosis of acute 
respiratory illness, apnea, asthma exacerbation, bronchiolitis, croup, cystic fibrosis 
exacerbation, febrile neonate, febrile seizure, fever without localizing signs, hypothermia, 
influenza, otitis media, other respiratory infection, paroxysmal cough, pharyngitis, 
pneumonia, respiratory distress, respiratory syncytial virus (RSV), rule-out sepsis, sinusitis, 
strep throat, tonsillitis, upper respiratory illness, or wheezing. Children presenting to the ED 
were eligible if they had a chief complaint of fever or respiratory symptoms (cough, earache, 
nasal congestion or runny nose, shortness of breath or rapid or shallow breathing, sore 
throat, vomiting after cough, or wheezing). Hospitalized children were excluded if they had 
a known nonrespiratory cause for admission, had been previously hospitalized during the 
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past 4 days, had remained hospitalized since birth, or had febrile neutropenia related to 
cancer treatment. Children presenting to the ED were excluded if they had been previously 
enrolled in the ED within the past 6 days.
Surveillance was conducted in the hospital Monday through Friday, excluding public 
holidays, and in the ED, 4–6 days per week in shifts of 6–8 hours per day. CCHMC accounts 
for >95% of hospitalizations and ED visits for children from Hamilton County.
Study Period
Children were enrolled from 1 July–31 October 2014. The study period was selected to 
capture EV-D68 circulation in the hospital catchment area during the 2014 US EV-D68 
outbreak [4]. Specimens collected in June and November 2014 from hospitalized patients 
enrolled in ARI surveillance at CCHMC all tested negative for EV-D68.
Data Collection and Definitions
Study personnel conducted parent or guardian interviews and medical record reviews using 
standardized study forms. The child’s sex, race, birth history, and history of current illness 
(duration, symptoms) were obtained by parental report. Medical history, hospital course, 
admission diagnosis, and insurance information were obtained by chart review.
For each participant preliminarily classified as having asthma or reactive airway disease on 
the basis of parental report or chart review, the CCHMC electronic medical record was 
reviewed by a pediatrician (M. A. S.) to confirm the classification. We defined asthma as a 
documented diagnosis in the medical record by a qualified healthcare provider prior to the 
child’s current illness. When available, data on asthma severity (intermittent or persistent) 
were also collected. Premature birth was defined as parental report of birth >1 month early. 
Chest radiographic findings were categorized as normal or abnormal based on the 
radiologist’s impression in the report.
Laboratory Testing
Midturbinate nasal and posterior pharyngeal swabs were collected from each participant and 
combined for testing. Respiratory virus testing using a multiplex polymerase chain reaction 
(PCR) assay (xTAG Respiratory Viral Panel, Luminex Molecular Diagnostics, Austin, 
Texas) was performed at CCHMC. All specimens were subsequently tested at the US 
Centers for Disease Control and Prevention (CDC) using a sensitive, CDC-developed EV-
D68 real-time reverse-transcription PCR assay [10]. Children were classified as having EV-
D68 infection if the nasal/throat specimen tested positive using the CDC assay with a cycle 
threshold (Ct) value ≤43; Ct values >43 were classified as equivocal, and specimens with no 
Ct were classified as negative. In the case of a specimen with a negative RNaseP assay result 
(RNA extraction control), the test result was considered inconclusive.
Statistical Analysis
Data from the study forms were entered into Redcap [11] at CCHMC and analyzed using 
Stata software version 12 (StataCorp, College Station, Texas). Characteristics of children 
with EV-D68 infection were compared to those of children with EV-D68–negative ARI. 
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Patients enrolled from the ED and inpatients were analyzed separately, except when 
combined for multivariate analysis of demographic and clinical factors associated with 
medically attended EV-D68 infection. Pearson χ2, Fisher exact test, or Wilcoxon rank-sum 
test were used as appropriate to compare categorical or continuous variables. All P values 
were 2-sided and evaluated for statistical significance at P < .05.
Rate Calculations
The number of EV-D68 hospitalizations and ED visits per 1000 children was calculated 
using weighted case numbers divided by the 2014 age-specific Hamilton County population 
according to the US Census Bureau [12]. For inpatients, individual records were inflated to 
account for the proportion of eligible children enrolled and the number of inpatient 
surveillance days out of all possible days during the study period [13]. The 95% confidence 
intervals (CIs) were calculated by using the 2.5th and 97.5th percentile values for EV-D68 
positive hospitalizations resulting from 1000 bootstrap samples [14]. ED visit rates were 
determined by using the number of ARI-related ED visits among study-eligible children for 
the 24-hour surveillance periods, inflating for days when surveillance was not conducted. 
The monthly totals of ARI-related ED visits were multiplied by the monthly proportion of 
study participants testing positive for EV-D68. Because of differences in the weighting 
methodology for the ED setting, 95% CIs were not calculated. Children testing positive for 
EV-D68 and admitted from the ED on an inpatient surveillance day were included in rate 
estimates for both ED visits and hospitalizations.
Ethics
The study was approved by the CCHMC institutional review board. Informed consent was 
obtained from each child’s parent or guardian before enrollment, and assent was obtained 
from children 7 years of age and older.
RESULTS
Study Population and EV-D68 Detection
From 1 July through 31 October 2014, 505 ED patients and 207 hospitalized patients were 
enrolled and had a conclusive test for EV-D68 (Figure 1). EV-D68 infection was detected in 
58 of 505 (11%) ED patients and 51 of 207 (25%) hospitalized patients. Most EV-D68 
infections occurred during August and September (Figure 2).
Characteristics of Children With EV-D68 Infection
The median age of all patients (ED and hospitalized) with EV-D68 infection was 2.9 (range, 
0.2–12.9) years and 62 of 109 (57%) were male. Sociodemographic characteristics of 
children with EV-D68 infection were similar to those of children with ARI from other 
causes, with the exception of race/ethnic group among ED patients (Table 1).
Compared with other causes of ARI, cough, difficulty breathing, and wheezing were 
significantly more common among ED and hospitalized patients with EV-D68 infection; 
coryza or rhinorrhea was more common among children with EV-D68 infection in the ED 
only (Table 2). Wheezing was significantly associated with EV-D68 infection even among 
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children without preexisting asthma. Children with EV-D68 infection presenting to the ED 
were less likely to have fever or sore throat compared to children with other causes of ARI 
(P = .02 and P = .007, respectively).
Preexisting asthma was associated with EV-D68 infection among ED and hospitalized 
patients (combined odds ratio [OR], 3.0; 95% CI, 1.9–4.5). This association remained 
significant after adjusting for age, sex, and race in multivariate analysis (adjusted OR, 3.2; 
95% CI, 2.0–5.1).
Hospitalization and ED Visit Rates
The rates of EV-D68 hospitalization were 1.3 (95% CI, 1.0–1.6) per 1000 children <13 years 
of age, 1.9 (95% CI, 1.4–2.6) per 1000 children <5 years of age, and 0.9 (95% CI, .6–1.2) 
per 1000 children 5 to <13 years of age. Rates of hospitalization were highest among 
children 6 months to <5 years of age (Table 3). The rates of EV-D68–associated ED visit 
were 8.4 per 1000 children <13 years of age, 15.3 per 1000 children <5 years of age, and 4.0 
per 1000 children 5 to <13 years of age.
Clinical Course of ED Patients
Of children enrolled in the ED, 29 of 505 (6%) required hospital admission; EV-D68 
infection accounted for 13 of the 29 (45%) ARI admissions. Children with EV-D68 infection 
were more likely to be admitted (13/58 [22%]) than children with other causes of ARI 
(16/446 [3.6%]) (P ≤ .001). Most children admitted with EV-D68 infection had asthma 
(10/13 [77%]). Admission was more common among children with asthma who had EV-D68 
infection compared to children with asthma and non-EV-D68 ARI (10/16 [63%] vs 6/64 
[9%]; P < .001).
Clinical Course of Inpatients
Among hospitalized children, those with EV-D68 infection more often required ICU 
admission, received oxygen, and had a chest radiograph performed compared to children 
with other causes of ARI (Table 4). EV-D68 accounted for 33 of 99 (33%) admissions 
among children with asthma during the study period, and 29 of 62 (47%) during the months 
with highest EV-D68 incidence (August and September). Among children with EV-D68, no 
significant differences in hospital course were observed between children with and without 
preexisting asthma (Table 5). All children hospitalized with ARI survived.
Other Respiratory Virus Detections
Respiratory viruses other than EV-D68 were detected in 245 of 505 (49%) children in the 
ED and 88 of 207 (43%) hospitalized children (Figure 3). Co-detection of other respiratory 
viruses was rare among children with EV-D68 infection, with 1 of 109 (<1%) also testing 
positive for human metapneumovirus (hMPV). The multiplex assay detected enterovirus/
rhinovirus in 106 of the 109 (97%) EV-D68 infections detected by the EV-D68-specific 
assay.
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DISCUSSION
During a season of high circulation, EV-D68 was detected in 25% of ARI hospitalizations 
and 11% of ARI ED visits among children <13 years of age at a large children’s hospital. 
We estimated the rate of hospitalization associated with EV-D68 infection among children 
<5 years of age in Hamilton County, Ohio, to be 1.9 per 1000 children; in studies using 
comparable methodology, this is higher than estimates for parainfluenza viruses (1.0–1.2 per 
1000 children), hMPV (1 per 1000 children), and influenza virus during seasons in 2000–
2011 (0.2–1.6 per 1000 children), which included the pandemic H1N1 season, but lower 
than for RSV (3–3.5 per 1000 children) [13, 15–22]. For children 5 to <13 years of age, 
published comparison data are limited; however, EV-D68 hospitalization rates were higher 
than those estimated for pneumonia attributed to influenza and other respiratory viruses 
among similar age groups during 2010–2012 [23]. The rate of ED visits for EV-D68 among 
children <5 years of age was similar to estimates for hMPV (6–17 per 1000 children) but 
lower than for RSV (21.5–28 per 1000 children) [17, 20, 24]; comparisons with influenza 
varied on the basis of season, but were lower than age-specific ED visit rates for the 
pandemic H1N1 season in one county with available estimates (19–29 per 1000 children) 
[15, 18, 25].
Preexisting asthma was significantly associated with medically attended EV-D68 infection, 
confirming observations from other studies [4, 9, 26, 27]. The prospective study design with 
systematic testing for EV-D68 is a strength of our study and reduced the potential for 
selection bias compared with case series or retrospective studies in which testing was 
performed on the basis of clinician discretion. During the peak of the outbreak, nearly half 
of ARI hospitalizations and a majority of ED admissions among children with asthma were 
associated with EV-D68 infection. Among children without a history of asthma, we 
observed significantly more wheezing in those with EV-D68 infection compared to other 
causes of ARI, a finding also previously reported from other studies and outbreak 
descriptions [27, 28].
The association between asthma exacerbation or acute wheezing and respiratory viruses, 
particularly rhinoviruses, is well documented [29–32]. Rhinovirus infection in patients with 
asthma has been associated with increased lower respiratory tract symptoms and clinical 
severity [33, 34]. Although rhinoviruses are most commonly implicated in acute wheezing 
hospitalizations, the relative contributions of rhinoviruses and respiratory enteroviruses 
might not be fully appreciated because of limitations of diagnostic tests. Commercial 
molecular assays do not differentiate between rhinoviruses and enteroviruses, and advances 
in molecular methods that allow more reliable differentiation are relatively recent. EV-D68 
and rhinoviruses are both members of the picornavirus family (and Enterovirus genus) and 
are phenotypically similar [35], which could explain similarities in clinical presentation in 
children with asthma.
In our study, the hospital course and outcome among children admitted with EV-D68 
infection did not differ on the basis of asthma status. Although children with asthma were 
more likely to have medically attended EV-D68 infection and were more often admitted 
from the ED, hospital outcomes were similar between children with and without preexisting 
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asthma. Some reports have shown a more severe clinical course among hospitalized children 
with EV-D68 infection who have preexisting asthma [4, 9], whereas others have not 
observed this difference [8]. It is possible that differences in study design or power could 
explain differences in findings. With the exception of asthma, underlying medical conditions 
were uncommon among children in our study and no significant associations with EV-D68 
infection were detected.
In both the ED and inpatient settings, children with EV-D68 infection had significantly more 
cough, difficulty breathing, and wheezing compared to children with other causes of ARI. 
Other reports have also documented these symptoms as predominant features of EV-D68 
ARI [4, 26, 28, 36]. This triad of symptoms was reported nearly universally among 
inpatients. In the ED, cough was most prominent (90%), whereas wheezing and difficulty 
breathing were present in 45% and 59%, respectively. A majority of ED patients with EV-
D68 illness also had nasal congestion or rhinorrhea, whereas fever and sore throat were less 
common compared with other causes of ARI. Our findings contribute to the limited available 
data on the spectrum of EV-D68 illness observed in the outpatient setting. Surveillance 
reports using influenza-like illness criteria (requiring objective fever) are likely to 
underestimate the number of EV-D68 cases and might not capture the full spectrum of 
respiratory illness seen in the outpatient setting given our finding that fever was reported in 
less than half of ED patients with EV-D68 illness.
EV-D68 infection was associated with an increased likelihood of admission from the ED 
and, among hospitalized patients, increased ICU admission compared with other causes of 
ARI. Children with EV-D68 illness were more often treated with oxygen and were more 
likely to receive a chest radiograph; however, differences in some other measures of disease 
severity such as the need for mechanical ventilation or duration of ICU stay were not 
observed. Consistent with our findings, hypoxia or the need for supplemental oxygen has 
been associated with EV-D68 infection in numerous reports [27, 28, 37, 38]. In a recent 
retrospective study comparing children with EV-D68 and H1N1 influenza illness, those with 
EV-D68 were more likely to require admission to the ICU and to receive noninvasive 
positive pressure ventilation (bilevel positive airway pressure or continuous positive airway 
pressure) but less likely to require intubation or to have severe outcomes or complications 
[26]. Our study supports other published data, and suggests that an EV-D68 epidemic may 
result in considerable respiratory morbidity and utilization of hospital resources, including 
intensive care, particularly among children with asthma; however, severe complications, 
prolonged hospitalization, and death have not been common features of EV-D68 respiratory 
illness. These findings have implications for epidemic planning. In particular, planning for 
an increased patient census in pediatric wards and ICUs, and increased demand for asthma 
therapeutics and respiratory equipment, may be important [6, 26, 39].
Our study was subject to limitations. Surveillance was conducted at a single tertiary-level 
hospital, and rates of EV-D68 infection might not be generalizable to other geographic 
locations or to hospitals serving different populations. EV-D68 rates represent a single 
epidemic season, and might not be directly comparable to rates of other respiratory viruses 
estimated over several years of surveillance at multiple sites. To calculate population- based 
rates, we assumed that eligible children who were not enrolled were similar to those 
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enrolled. Our age criterion for enrollment (<13 years old) excluded older children who could 
have had EV-D68 infection, and this is likely reflected in the lower median age for EV-D68 
infection in our study compared with studies that included all ages [4]. We excluded children 
with febrile neutropenia, which may have limited our ability to evaluate the association 
between EV-D68 infection and immunosuppression. We included only symptoms typically 
associated with respiratory infections on our interview form; therefore, it is possible that we 
did not capture the full spectrum of symptoms associated with EV-D68 respiratory illness.
In conclusion, during the 2014 EV-D68 epidemic, population- based rates of hospitalization 
were generally higher than estimates for other respiratory viruses during their typical 
seasons, with the exception of RSV among children <5 years of age. These rates reflect a 
period of high EV-D68 circulation, which has not been observed in subsequent years (2015 
or 2016) [5]. Children with preexisting asthma appear to be at increased risk for medically 
attended EV-D68 illness. Continued surveillance and vigilance among clinicians for EV-D68 
infection, particularly during late summer and early autumn in the United States, is 
important. In the instance of a season with high EV-D68 activity, anticipating increased 
healthcare utilization and increased demand for asthma therapeutics and respiratory 
equipment may be prudent.
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Figure 1. 
A, Inpatient enrollment flow diagram. B, Emergency department enrollment flow diagram.
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Figure 2. 
Enterovirus D68 (EV-D68)–positive tests among hospitalized and emergency department 
patients <13 years of age with acute respiratory illness, weekly number and percentage 
positive, Cincinnati, Ohio, 1 June–30 November 2014. Test results for June and November 
represent hospitalized children only.
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Figure 3. 
Respiratory viruses detected among hospitalized and emergency department (ED) patients 
<13 years of age with acute respiratory illness using a commercial multiplex assay, 1 July–
31 October 2014. Labels display No. (%). Among hospitalized patients, co-detection of >1 
respiratory virus occurred in 3 of 207 (1%) children. Among ED patients, co-detection of >1 
respiratory virus occurred in 17 of 505 (3%) children. Abbreviations: ADV, adenovirus; EV-
D68, enterovirus D68; EV/RV, enterovirus/rhinovirus (excluding EV-D68 in this figure); 
HMPV, human metapneumovirus; PIV, parainfluenza virus; RSV, respiratory syncytial virus.
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Table 3
Rates of Hospitalization and Emergency Department Visit for Enterovirus D68 Infection Among Children 
Residing in Hamilton County, Ohio, 1 July–31 October 2014, by Age
Age
Emergency Department Hospitalized
No. of EV-D68 Infections per 1000 Children (95% CI)
0 to <6 mo
…
a 0.6 (.0–2.2)
6 to <12 mo
…
a 2.8 (.6–5.6)
12 to <24 mo
…
a 2.9 (1.3–4.6)
24 to <60 mo
…
a 1.7 (1.0–2.4)
0 to <60 mo 15.3 1.9 (1.4–2.6)
60 mo to <13 y 4.0 0.9 (.6–1.2)
0 to <13 y 8.4 1.3 (1.0–1.6)
Abbreviations: CI, confidence interval; EV-D68, enterovirus D68.
aNot calculated.
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Table 4
Hospital Course and Outcomes for Children <13 Years of Age With Enterovirus D68 (EV-D68)–Positive and 
EV-D68–Negative Acute Respiratory Illness, Cincinnati, Ohio, 1 July–31 October 2014
Characteristic EV-D68 Positive (n = 51) EV-D68 Negative (n = 156) P Value
Inpatient length of stay, d
 Median 2 2 .88
 Range 1–6 0–11
Admission diagnosis, No. (%)
 LRTIa 51 (100) 106 (68) <.001
 Asthma exacerbation or RAD 39 (76) 68 (44) <.001
 Bronchiolitis 5 (10) 15 (10) …
 Pneumonia or pneumonitis 5 (10) 14 (9) …
  Wheezing 2 (4) 9 (6) …
Admitted to ICU, No. (%) 15 (29) 25 (16) .04
 ICU length of stay, d
 Median 2 2 .41
 Range 1–8 1–7
Oxygen received, No. (%) 38 (75) 73 (47) .001
Intubated, No. (%) 2 (4) 4 (3) .64
CXR done, No. (%) 35 (69) 77 (49) .02
 Abnormal CXR, No. (%)b 27/35 (77) 55/77 (71) .53
Outcome, No. (%)
 Survived 51 (100) 156 (100) …
Abbreviations: CXR, chest radiograph; EV-D68, enterovirus D68; ICU, intensive care unit; LRTI, lower respiratory tract infection; RAD, reactive 
airway disease.
a
LRTI defined as asthma exacerbation or RAD, bronchiolitis, cystic fibrosis exacerbation, pneumonia or pneumonitis, or wheezing.
bChest radiograph findings were categorized as normal or abnormal based on the radiologist’s impression in the report.
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Table 5
Hospital Course and Outcomes for Children <13 Years of Age With Enterovirus D68 Infection With and 
Without Asthma, Cincinnati, Ohio, 1 July–31 October 2014
Characteristic Asthma (n = 33) No Asthma (n = 18) P Value
Length of stay, d
 Median 1 2 .13
 Range 1–6 1–6
Admission diagnosis, No. (%)
 LRTIa 33 (100) 18 (100) …
  Asthma exacerbation or RAD 31 (94) 8 (44) …
  Bronchiolitis 0 5 (28) …
  Pneumonia or pneumonitis 0 5 (28) …
  Wheezing 2 (6) 0 …
Admitted to ICU, No. (%) 9 (27) 6 (33) .65
 ICU length of stay, d
  Median 2 2 .39
  Range 1–8 1–4
Oxygen received, No. (%) 23 (70) 15 (83) .34
Intubated, No. (%) 1 (3) 1 (6) 1.00
CXR done, No. (%) 20 (61) 15 (83) .12
 Abnormal CXR, No. (%) 16/20 (80) 11/15 (73) .70
Abbreviations: CXR, chest radiograph; ICU, intensive care unit; LRTI, lower respiratory tract infection; RAD, reactive airway disease.
a
LRTI defined as asthma exacerbation or RAD, bronchiolitis, cystic fibrosis exacerbation, pneumonia or pneumonitis, or wheezing.
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